National Grid plc (NGG) Announces its FY 2025 Results
National Grid plc (NYSE:NGG) is the UK's largest electricity distribution network, serving nearly 8 million customers in the country. The company also operates in the US, delivering electricity, natural gas, and clean energy to more than 20 million people throughout New York and Massachusetts.
National Grid plc (NYSE:NGG) recently posted its results for FY 2025, reporting an underlying EPS of 73.3p, up 2% from the previous year and ahead of guidance, with the underlying operating profit increase more than offsetting the increased number of shares after the Rights Issue. Moreover, the company's record £9.8 billion of capital investment helped to drive regulated asset growth of 10.5%. However, revenue decreased by 7% YoY to £18.38 billion. NGG's cash flow generated from continuing operations during the year came in at £7 billion, £0.3 billion lower than last year, mainly due to adverse timing movements.
National Grid plc (NYSE:NGG) also declared a total dividend of 46.72p for its shareholders, an increase of 3.21% on last year's rebased dividend. As of the end of FY 2025, the company had £18 billion of distributable reserves, which is sufficient to cover more than five years of forecast dividends.
National Grid plc (NYSE:NGG) has earmarked tens of billions of pounds in capital expenditure over the coming years to upgrade the UK's grid system, and recently raised £7bn via a share placing from investors to fund its growth and strengthen its balance sheet.
John Pettigrew, CEO of National Grid plc (NYSE:NGG), stated:
"We've made significant progress in the first year of our five-year financial framework, with record capital investment of almost £10 billion, 20% higher than 2024, helping to drive regulated asset growth of around 10% this year. Strong performance across all areas of the business underpins our plans to successfully invest c.£60 billion over five years. At a time of international economic uncertainty, National Grid continues to provide stable and predictable growth through our resilient business model. We remain focused on delivering secure, affordable and clean energy to our customers and communities, and providing long-term value and returns for our shareholders."
While we acknowledge the potential of NGG to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NGG and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Cheap Energy Stocks to Buy Now and 10 Most Undervalued Energy Stocks According to Hedge Funds.
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
B&G Foods Inc (BGS) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
Net Sales: $424.4 million, down 4.5% year-over-year. Adjusted EBITDA: $58 million, down 9.3% from the previous year. Adjusted EBITDA Margin: 13.7% of net sales. Adjusted Diluted Earnings Per Share: $0.04. Base Business Net Sales: Decreased by 4.2% year-over-year. Gross Profit: $87 million, representing 20.5% of net sales. Adjusted Gross Profit: $89.1 million, or 21% of net sales. Net Cash from Operations: $17.8 million in Q2 2025. Net Debt: Reduced to $1.957 billion at the end of Q2 2025. Interest Expense: $35.8 million for Q2 2025. Divestitures: Completed divestitures of Don Pepino, Sclafani, and Le Sueur brands. Revised Fiscal Year 2025 Guidance: Net sales of $1.83 billion to $1.88 billion; adjusted EBITDA of $273 million to $283 million; adjusted EPS of $0.50 to $0.60. Warning! GuruFocus has detected 7 Warning Signs with BGS. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points B&G Foods Inc (NYSE:BGS) demonstrated sequential improvement in trend and performance in Q2 2025 after a challenging Q1. The company completed two key divestitures, which are expected to sharpen focus, simplify the business, and improve margins and cash flow. The U.S. frozen vegetables business is expected to turn profitable in the second half of 2025, with a projected increase in segment adjusted EBITDA. B&G Foods Inc (NYSE:BGS) is committed to reducing leverage and expects to reduce it to 6x within the next 12 months. Cash flow continues to be strong, with $17.8 million generated in net cash from operations during Q2 2025, up from $11.3 million in Q2 2024. Negative Points Q2 2025 net sales were down 4.5% compared to the previous year, with base business net sales down 4.2%. Adjusted EBITDA for Q2 2025 was $58 million, a decrease of 9.3% compared to the previous year. The frozen and vegetables business unit experienced a significant decline in segment adjusted EBITDA due to higher costs and trade spend. The specialty business unit saw an 8% decline in net sales, primarily due to lower Crisco oil pricing. Selling, general, and administrative expenses increased by 9.4% in Q2 2025 compared to the previous year, impacting overall profitability. Q & A Highlights Q: Bruce, can you clarify the expected decline in core business sales for the second half of 2025? A: Yes, excluding divestitures, we expect base business sales to be down about 1% for the second half. This includes a benefit from the 53rd week, which will add approximately $15 million to $20 million in sales during the fourth quarter. Q: How are you planning to mitigate the impact of tariffs, particularly in the spices and flavor solutions segment? A: We are implementing targeted pricing actions to recover tariff costs, primarily affecting garlic and black pepper sourced from China and Vietnam. There will be some lag due to retailer lead times, but we expect to offset some of the impact with productivity and cost savings efforts. Q: Can you provide more details on the impact of recent divestitures on your guidance for the year? A: The guidance adjustment is primarily due to the divestitures. The outlook for the second half remains consistent with our expectations following the first quarter results. Q: What is the status of your spices and seasonings business, and are you seeing any benefits from increased home cooking? A: The spices and seasonings business is not fully meeting our expectations. We anticipate slight growth in the second half, supported by targeted pricing to recover tariff impacts. The category is benefiting from increased demand for fresh proteins. Q: Are there any plans to change sourcing strategies to mitigate tariff impacts on spices and seasonings? A: We are exploring alternative sourcing options, but most spices are grown in regions already subject to tariffs. We have found some alternative sources for garlic and onion outside of China, but pricing adjustments will still be necessary. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Waters Corp (WAT) Q2 2025 Earnings Call Highlights: Strong Sales Growth and Raised Guidance
Sales Growth: 9% as reported, 8% in constant currency. Non-GAAP EPS: $2.95, up 12% year-on-year. GAAP EPS: $2.47. Pharma Growth: 11% growth in the Pharma segment. Industrial Growth: 6% growth in the Industrial segment. Academic and Government: Declined 3%. Gross Margin: 58.3% for the quarter. Adjusted Operating Margin: 29.1%. Free Cash Flow: $159 million after $23 million in capital expenditures. Net Debt Position: $1.1 billion at the end of the quarter. Full Year 2025 Sales Growth Guidance: Raised to 5.5% to 7.5% in constant currency. Full Year 2025 Non-GAAP EPS Guidance: Raised to $12.95 to $13.05. Third Quarter 2025 Sales Growth Guidance: 5% to 7% in constant currency. Third Quarter 2025 EPS Guidance: $3.15 to $3.25. Warning! GuruFocus has detected 2 Warning Sign with WAT. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Waters Corp (NYSE:WAT) reported strong sales growth of 9% as reported and 8% in constant currency, exceeding the high end of their guidance. Non-GAAP earnings per share increased by 12% year-on-year to $2.95, surpassing the midpoint of their guidance. The company experienced significant growth in its LC and mass spec portfolio, with instruments growing mid-single digits and recurring revenue up 11%. Waters Corp (NYSE:WAT) raised its full-year 2025 constant currency sales growth guidance to 5.5% to 7.5% and increased its non-GAAP EPS guidance to $12.95 to $13.05. The company is successfully expanding into high-growth areas, with GLP testing revenue growing 70% year-over-year and PFAS testing revenue increasing over 50% year-over-year. Negative Points The TA division experienced weakness, particularly in macro-sensitive polymer and materials testing applications, leading to a decline in sales. Academic and government segments underperformed, declining by 3%, despite better-than-expected performance. The operating tax rate presented a $0.05 headwind to adjusted EPS due to jurisdictional mix and discrete items specific to the quarter. The company faced margin dilution from tariff surcharges, impacting the gross margin for the quarter. The TA business in the Americas declined by 20% due to macroeconomic conditions and tariff challenges affecting material science and polymers customers. Q & A Highlights Q: Can you provide an update on the replacement cycle in LC and competitive dynamics, particularly regarding the Alliance iS? A: Udit Batra, President and CEO, explained that LCMS continued to grow high single digits, with strong replacement activity across large pharma customers, especially in the US and Europe. The Alliance iS grew 300% year-over-year, contributing significantly to this growth. Additionally, the TQ Absolute XR instrument has shown exceptional robustness, allowing for significant improvements in testing capabilities. Q: Regarding the BD acquisition, what is the timeline for bringing new products to market, particularly in mass spec and MALDI for microbiology? A: Udit Batra noted that while the microbiology opportunities are not included in the deal model, the team is excited about the potential. The development of new products in this area could take two to five years, with a total addressable market of around $400 million to $500 million. Q: What are your expectations for LCMS growth in the second half of the year, given the high single-digit growth in Q2? A: Udit Batra stated that the replacement cycle remains strong, particularly in large pharma, CDMOs, and generics. The TQ Absolute XR has exceeded expectations, and the company is confident in continued growth. Amol Chaubal, CFO, added that the guidance assumes a conservative 5% instrument growth, not fully reflecting the strong funnel and momentum. Q: Can you elaborate on the margin dynamics and the impact of tariffs in Q2? A: Amol Chaubal explained that the margin impact was primarily on the gross margin line due to geographical mix and costs associated with tariff remediation. The tax rate also created a $0.05 headwind on EPS. Margins are expected to improve progressively in Q3 and Q4. Q: How sustainable is the growth in China, and what are the expectations for the second half of the year? A: Udit Batra highlighted that China grew double digits in Q2, with strength across all end markets. The company remains conservative in its guidance for the second half, assuming low to mid-single-digit growth, despite strong performance in CDMOs and battery testing. Q: What are the expectations for the academic and government (ANG) segment, given recent funding dynamics? A: Udit Batra noted that ANG declined 3% in Q2, ahead of expectations. The company remains conservative for the second half, assuming continued decline, despite some positive funding news. Growth in China was strong due to localization and modest stimulus impact. Q: How do you plan to achieve the $290 million synergy target post-acquisition of BD's Biosciences and Diagnostic Solutions? A: Udit Batra outlined that immediate impacts are expected from instrument replacement, service attach rate improvements, and e-commerce expansion. The company plans to leverage its existing operational discipline to achieve these synergies quickly. Q: What is the outlook for the drug discovery business within the pharma segment? A: Udit Batra stated that pharma drug discovery remains slow, with no significant replacement cycle activity. However, large pharma and CDMOs are experiencing healthy replacement cycles and order conversion. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
BP's profit in Q2 declines year-over-year but beats estimates
-- BP (NYSE:BP) (LON:BP) on Tuesday reported second-quarter profit that beat analyst expectations, rebounding amid recent volatility in global oil and gas markets. The company's underlying replacement cost (RC) profit for the period rose to $2.4 billion from $1.4 billion in Q1, supported by improved performance across its segments. The figure marked a decline from the $2.76 billion reported in the year-ago quarter, though it still topped analyst estimates of $1.81 billion, according to an LSEG-compiled consensus. Operating cash flow came in at $6.3 billion, up from $2.8 billion in the prior quarter, despite including a $1.1 billion Gulf of Mexico settlement payment. The oil production and operations unit generated $2.3 billion in underlying RC profit, although this was below last year's levels due to weaker realized prices and higher depreciation. Production rose 2.5% year-over-year to 1.52 million barrels of oil equivalent per day. Realized liquids prices declined to $59.74/bbl from $73.05 a year ago. Gas & low carbon energy delivered $1.5 billion in underlying RC profit, broadly flat year-on-year, with lower production offset by higher margins. Reported production in the segment was down 13% due to divestments in Egypt and Trinidad. The customers & products segment saw underlying RC profit improve to $1.5 billion from $1.1 billion a year ago, as stronger trading and midstream performance offset a weaker refining margin environment. BP-operated refining availability remained high at 96.4%. 'We are delivering our plan with operational reliability above 96%," said CEO Murray Auchincloss in the release. "We remain fully focused on delivering safely and reliably, maintaining capital discipline and driving performance improvement.' He also noted that the company is conducting a strategic review of its business portfolio 'to ensure we are maximizing shareholder value.' BP's capital expenditure for the quarter stood at $3.4 billion. Net debt fell to $26.0 billion from $27.0 billion in Q1, helped by divestment proceeds of $1.4 billion. The company also raised its dividend by 4% to 8.32 cents per share and announced a new $750 million share buyback program. Related articles BP's profit in Q2 declines year-over-year but beats estimates These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia 7 Undervalued Stocks on the Rise With 50%+ Upside Potential
